[1] Ostrom QT, Gittleman H, Liao P, et al.  Cbtrus Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011[J]. Neuro Oncol, 2014, 16(Suppl 4): Siv1-iv63.   doi: 10.1093/neuonc/nou223
[2] Okada M, Miyake K, Tamiya T.  Glioblastoma Treatment in the Elderly[J]. Neurol Med Chir (Tokyo), 2017, 57(12): 667-676.   doi: 10.2176/nmc.ra.2017-0009
[3] Park KS, Lee HW, Park SH, et al.  The clinical significance of fascin expression in a newly diagnosed primary glioblastoma[J]. J Neurooncol, 2016, 129(3): 495-503.   doi: 10.1007/s11060-016-2200-3
[4] Louis DN, Perry A, Reifenberger G, et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary[J]. Acta Neuropathol, 2016, 131(6): 803-820.   doi: 10.1007/s00401-016-1545-1
[5] Nabors LB, Portnow J, Ammirati M, et al.  NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017[J]. J Natl Compr Canc Netw, 2017, 15(11): 1331-1345.   doi: 10.6004/jnccn.2017.0166
[6] Cheng HB, Yue W, Xie C, et al.  IDH1 mutation is associated with improved overall survival in patients with glioblastoma: a meta-analysis[J]. Tumour Biol, 2013, 34(6): 3555-3559.   doi: 10.1007/s13277-013-0934-5
[7] Turcan S, Rohle D, Goenka A, et al.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype[J]. Nature, 2012, 483(7390): 479-483.   doi: 10.1038/nature10866
[8] Hegi ME, Diserens AC, Godard S, et al.  Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide[J]. Clin Cancer Res, 2004, 10(6): 1871-1874.   doi: 10.1158/1078-0432.CCR-03-0384
[9] Reifenberger G, Hentschel B, Felsberg J, et al.  Predictive impact of MGMT promoter methylation in glioblastoma of the elderly[J]. Int J Cancer, 2012, 131(6): 1342-1350.   doi: 10.1002/ijc.27385
[10] Batchelor TT, Betensky RA, Esposito JM, et al.  Age-Dependent Prognostic Effects of Genetic Alterations in Glioblastoma[J]. Clin Cancer Res, 2004, 10(1): 228-233.   doi: 10.1158/1078-0432.CCR-0841-3
[11]

Bozdag S, Li AG, Riddick G, et al. Age-Specific Signatures of Glioblastoma at the Genomic, Genetic, and Epigenetic Levels[J/OL]. PLoS One, 2013, 8(4): e62982[2018-11-16]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639162. DOI: 10.1371/journal.pone.0062982.
[12] Parsons DW, Jones S, Zhang XS, et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme[J]. Science, 2008, 321(5897): 1807-1812.   doi: 10.1126/science.1164382
[13]

Arita H, Yamasaki K, Matsushita Y, et al. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas[J/OL]. Acta Neuropathol Commun, 2016, 4: 79[2018-11-16]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977715. DOI: 10.1186/s40478-016-0351-2.
[14] Vuorinen V, Hinkka S, Färkkilä M, et al.  Debulking or biopsy of malignant glioma in elderly people—a randomised study[J]. Acta Neurochir (Wien), 2003, 145(1): 5-10.   doi: 10.1007/s00701-002-1030-6
[15] Almenawer SA, Badhiwala JH, Alhazzani W, et al.  Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis[J]. Neuro Oncol, 2015, 17(6): 868-881.   doi: 10.1093/neuonc/nou349
[16] Perry JR, Laperriere N, O'Callaghan CJ, et al.  Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma[J]. N Engl J Med, 2017, 376(11): 1027-1037.   doi: 10.1056/NEJMoa1611977
[17] Chaichana KL, Garzon-Muvdi T, Parker S, et al.  Supratentorial Glioblastoma Multiforme: The Role of Surgical Resection Versus Biopsy Among Older Patients[J]. Ann Surg Oncol, 2011, 18(1): 239-245.   doi: 10.1245/s10434-010-1242-6
[18] Keime-Guibert F, Chinot O, Taillandier L, et al.  Radiotherapy for Glioblastoma in the Elderly[J]. N Engl J Med, 2007, 356(15): 1527-1535.   doi: 10.1056/NEJMoa065901
[19] Scott J, Tsai YY, Chinnaiyan P, et al.  Effectiveness of radiotherapy for elderly patients with glioblastoma[J]. Int J Radiat Oncol Biol Phys, 2011, 81(1): 206-210.   doi: 10.1016/j.ijrobp.2010.04.033
[20] Marijnen CAM, van den Berg SMP, van Duinen SG, et al.  Radiotherapy is effective in patients with glioblastoma multiforme with a limited prognosis and in patients above 70 years of age: A retrospective single institution analysis[J]. Radiother Oncol, 2005, 75(2): 210-216.   doi: 10.1016/j.radonc.2005.03.004
[21] Idbaih A, Taillibert S, Simon JM, et al.  Short course of radiation therapy in elderly patients with glioblastoma multiforme[J]. Cancer Radiother, 2008, 12(8): 788-792.   doi: 10.1016/j.canrad.2008.05.007
[22] Roa W, Brasher PMA, Bauman G, et al.  Abbreviated Course of Radiation Therapy in Older Patients With Glioblastoma Multiforme: A Prospective Randomized Clinical Trial[J]. J Clin Oncol, 2004, 22(9): 1583-1588.   doi: 10.1200/JCO.2004.06.082
[23] Lutterbach J, Ostertag C.  What Is the Appropriate Radiotherapy Protocol for Older Patients With Newly Diagnosed Glioblastoma?[J]. J Clin Oncol, 2005, 23(12): 2869-2870.   doi: 10.1200/JCO.2005.05.238
[24] Malmström A, Grønberg BH, Marosi C, et al.  Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial[J]. Lancet Oncol, 2012, 13(9): 916-926.   doi: 10.1016/S1470-2045(12)70265-6
[25] Chinot OL, Barrie M, Frauger E, et al.  Phase Ⅱ study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations[J]. Cancer, 2004, 100(10): 2208-2214.   doi: 10.1002/cncr.20224
[26] Gállego Pérez-Larraya J, Ducray F, Chinot O, et al.  Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase Ⅱ Trial[J]. J Clin Oncol, 2011, 29(22): 3050-3055.   doi: 10.1200/JCO.2011.34.8086
[27] Wick W, Platten M, Meisner C, et al.  Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial[J]. Lancet Oncol, 2012, 13(7): 707-715.   doi: 10.1016/S1470-2045(12)70164-X
[28]

Yin AA, Zhang LH, Cheng JX, et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in Elderly Glioblastoma Patients: A Meta-Analysis[J/OL]. PLoS One, 2014, 9(1): e85102[2018-11-16]. https://www.ncbi.nlm.nih.gov/pubmed/24454798. DOI: 10.1371/journal.pone.0085102.
[29] Chinot OL, Wick W, Mason W, et al.  Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma[J]. N Engl J Med, 2014, 370(8): 709-722.   doi: 10.1056/NEJMoa1308345
[30] Gilbert MR, Dignam JJ, Armstrong TS, et al.  A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma[J]. N Engl J Med, 2014, 370(8): 699-708.   doi: 10.1056/NEJMoa1308573
[31] Babu R, Komisarow JM, Agarwal VJ, et al.  Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival[J]. J Neurosurg, 2016, 124(4): 998-1007.   doi: 10.3171/2015.4.JNS142200